AstraZeneca (AZN.L): Mixed lung cancer updates across the portfolio; eVOLVE-Lung02 discontinuation improves 2027 catalyst set up 17 August 2026 | 8:52AM BST Equity Research This morning, AZN announced: 1) positive topline results from the Phase 3 SAFFRON trial, where Tagrisso plus Orpathys (MET inhibitor) showed positive PFS and OS results in 2L EGFR+ MET+ NSCLC; 2) discontinuation of the Phase 3 eVOLVE-Lung02 trial testing volrustomig (PD-1xCTLA-4) + chemo vs. Keytruda + chemo in PD-L1 low (<50%) NSCLC at ...